Most investors would view Royalty Pharma (NASDAQ: RPRX) as a disappointment. The company conducted its much-heralded initial public offering (IPO) last year. Shares ended 2020 up only 12%, well below the major market indexes. Its stock is in negative territory so far this year.
Royalty Pharma announced its fourth-quarter results before the market opened on Wednesday. And it didn't completely disappoint investors even though the healthcare stock slipped a little after the update. Here are the highlights from Royalty Pharma's Q4 results.
Image source: Getty Images.
For further details see:
Here's What Caused Royalty Pharma's Mixed Results in Q4